Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piroxicam + lidocaine is a topical or locally administered combination of two active pharmaceutical ingredients: piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), and lidocaine, a local anesthetic. Piroxicam acts primarily by inhibiting cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins involved in inflammation and pain signaling. Lidocaine works by blocking voltage-gated sodium channels on neuronal cell membranes, thereby preventing the initiation and conduction of nerve impulses responsible for pain sensation. This combination is used to provide both anti-inflammatory effects and local anesthesia for enhanced pain relief in various clinical settings such as minor surgical procedures, gynecological interventions (e.g., aspiration curettage), extracorporeal shock wave lithotripsy (ESWL), and potentially other painful conditions requiring both analgesia and reduction of inflammation[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piroxicam + lidocaine.